Biogen Inc. (BIIB) – What Are Researchers Thinking About This Stock?

Biogen Inc. (NASDAQ:BIIB) has earned a consensus recommendation of “Moderate Buy” from the thirty-two research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, twelve have given a hold recommendation, eighteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $236.04.

Several equities analysts have recently weighed in on BIIB shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research report on Monday, June 22nd. Bank of America cut their target price on shares of Biogen from $217.00 to $215.00 and set a “neutral” rating for the company in a research note on Tuesday, July 21st. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Jefferies Financial Group reiterated a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a research note on Wednesday, July 29th.

Institutional Investors Weigh In On Biogen

Institutional investors have recently made changes to their positions in the company. Forum Financial Management LP grew its holdings in Biogen by 2.4% in the 3rd quarter. Forum Financial Management LP now owns 1,936 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 46 shares in the last quarter. Kintegral Advisory LLC lifted its holdings in shares of Biogen by 0.6% during the third quarter. Kintegral Advisory LLC now owns 18,048 shares of the biotechnology company’s stock worth $4,077,000 after buying an additional 102 shares in the last quarter. TD Waterhouse Canada Inc. boosted its position in shares of Biogen by 313.8% in the third quarter. TD Waterhouse Canada Inc. now owns 2,855 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 2,165 shares during the period. Hanson & Doremus Investment Management grew its stake in shares of Biogen by 55.4% in the third quarter. Hanson & Doremus Investment Management now owns 816 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 291 shares in the last quarter. Finally, Pension & Wealth Management Advisors Inc. acquired a new position in shares of Biogen in the third quarter valued at about $81,000. Institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB traded down $2.70 during trading hours on Friday, reaching $232.65. The company’s stock had a trading volume of 1,462,624 shares, compared to its average volume of 1,309,491. Biogen has a 52 week low of $138.00 and a 52 week high of $240.99. The company’s 50-day moving average is $219.97 and its 200-day moving average is $203.85. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm has a market cap of $34.37 billion, a PE ratio of 41.18, a price-to-earnings-growth ratio of 2.61 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. During the same quarter last year, the firm posted $5.47 EPS. The company’s quarterly revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts forecast that Biogen will post 12.38 EPS for the current year.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.